Strategic Acquisition Recent sale of Harmonic Bionics assets to Bioness indicates a potential exit or partnership pathway for continuity of the Harmony SHR product line. Upsell or integration opportunities may exist with Bioness customers or in markets where Bioness has footprint.

Global Distribution Existing international distribution via Healthlink Holdings Limited to Hong Kong and Macau suggests a model to scale through regional partners; targeted outreach to similar distributors in Europe, UAE, or Asia could accelerate market penetration for rehabilitation robotics.

Clinical Footprint Commercial launch and first US installation at a top neurological hospital mark credible clinical validation; focus sales outreach to large neuro-rehab centers, university hospitals, and VA systems seeking objective measurement in movement disorder therapies.

Evidence-Driven Value Harmony SHR’s data capabilities enable baseline and progression measurements; frame pitches around outcomes such as functional assessment, therapy optimization, and research collaboration to attract hospitals, research groups, and payers prioritizing value-based care.

Funding & Growth Current revenue range and modest funding stage imply opportunities for strategic partnerships, co-development with larger medical device players, or seeking follow-on capital aligned with expanding sales, service infrastructure, and international deployments.